Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05070247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05070247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Terminated
Start date
April 14, 2022
Completion date
January 6, 2025
Enrollment
61 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, esophageal cancer, gastric cancer, hepatocellular cancer, kidney cancer, mesothelioma, nasopharyngeal cancer, non-small cell lung cancer (nsclc), non-squamous, pancreatic cancer, squamous cell cancer of head and neck (scchn)